Vor Bio VOR
Vor Bio (Nasdaq: VOR) is an immunology/inflammation drug developer. Its lead program, telitacicept (UPSTREAM MG), is in Phase 3 for generalized myasthenia gravis (gMG). Its next catalyst on record is telitacicept (UPSTREAM MG): Topline data (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: telitacicept (UPSTREAM MG) — Topline data (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| telitacicept (UPSTREAM MG) | generalized myasthenia gravis (gMG) | biologic-other | Phase 3 |
| telitacicept (UPSTREAM oMG) | ocular myasthenia gravis (oMG) | biologic-other | Phase 3 |
| telitacicept (UPSTREAM SjD) | Sjögren's disease (SjD) | biologic-other | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Celldex Therapeutics, Inc. CLDX
- Biohaven Ltd. BHVN
- BioCryst Pharmaceuticals, Inc. BCRX
- Zenas BioPharma ZBIO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.